• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多脏器切除术治疗原发性胰腺印戒细胞癌。

Multivisceral resection for primary pancreatic signet ring cell carcinoma.

机构信息

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

出版信息

Clin J Gastroenterol. 2023 Jun;16(3):482-487. doi: 10.1007/s12328-023-01783-0. Epub 2023 Mar 20.

DOI:10.1007/s12328-023-01783-0
PMID:36939986
Abstract

Primary pancreatic signet ring cell carcinoma (PPSRCC) is a rare and aggressive tumor with poor prognosis. Here, we report a case of PPSRCC treated with curative surgery. A 49-year-old man presented with right mid-abdominal pain. Imaging tests showed a 3.6 cm tumor extending around the head of the pancreas, the second portion of the duodenum, and the retroperitoneum. Involvement of the right proximal ureter resulted in moderate right hydronephrosis. A subsequent tumor biopsy revealed suspected pancreatic adenocarcinoma. No apparent lymph node or remote metastases were observed. The tumor was considered resectable, and radical pancreaticoduodenectomy was planned. Pancreaticoduodenectomy, right nephroureterectomy, and right hemicolectomy were conducted to resect the tumor en bloc. Final pathology revealed a poorly differentiated ductal adenocarcinoma of the pancreas with signet ring cells infiltrating the right ureter and transverse mesocolon (pT3N0M0, stage IIA, according to UICC for International Cancer Control TNM classification). The postoperative course was uneventful, and oral fluoropyrimidine (S-1) was administered as adjuvant chemotherapy for 1 year. At the 16-month follow-up, the patient was alive without any evidence of recurrence. Pancreaticoduodenectomy with right hemicolectomy and right nephroureterectomy was performed for curative resection of PPSRCC infiltrating the transverse mesocolon and right ureter.

摘要

原发性胰腺印戒细胞癌(PPSRCC)是一种罕见且侵袭性强、预后差的肿瘤。在此,我们报告一例经根治性手术治疗的 PPSRCC 病例。一名 49 岁男性因右中腹部疼痛就诊。影像学检查显示胰腺头部、十二指肠第二段和腹膜后有一个 3.6cm 的肿瘤,右侧近端输尿管受累导致中度右肾积水。随后的肿瘤活检提示疑似胰腺腺癌。未观察到明显的淋巴结或远处转移。肿瘤被认为可切除,并计划进行根治性胰十二指肠切除术。实施胰十二指肠切除术、右肾输尿管切除术和右半结肠切除术整块切除肿瘤。最终病理显示胰腺浸润性低分化导管腺癌,伴有印戒细胞浸润右侧输尿管和横结肠系膜(根据 UICC 国际癌症控制 TNM 分类,pT3N0M0,IIA 期)。术后过程顺利,给予口服氟嘧啶(S-1)辅助化疗 1 年。随访 16 个月时,患者存活且无复发迹象。实施胰十二指肠切除术联合右半结肠切除术和右肾输尿管切除术,对浸润横结肠系膜和右侧输尿管的 PPSRCC 进行根治性切除。

相似文献

1
Multivisceral resection for primary pancreatic signet ring cell carcinoma.多脏器切除术治疗原发性胰腺印戒细胞癌。
Clin J Gastroenterol. 2023 Jun;16(3):482-487. doi: 10.1007/s12328-023-01783-0. Epub 2023 Mar 20.
2
Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature.原发性胰腺印戒细胞癌:一例报告并文献复习
J Pancreat Cancer. 2021 Jan 21;7(1):1-7. doi: 10.1089/pancan.2020.0013. eCollection 2021.
3
Primary signet ring cell carcinoma of the pancreas with a good response to chemotherapy: case report and literature review.胰腺原发性印戒细胞癌对化疗反应良好:病例报告及文献综述
Tumori. 2017 Nov 15;103(Suppl. 1):e50-e52. doi: 10.5301/tj.5000671.
4
Signet-ring cell carcinoma co-existing with adenocarcinoma of the ampulla of vater. A case report.印戒细胞癌与壶腹腺癌并存。病例报告。
JOP. 2011 Mar 9;12(2):162-6.
5
Radical resection in signet ring carcinoma of the ampulla of Vater: report of an 11-year survivor.壶腹腺癌根治性切除术:一名存活11年患者的报告
Am Surg. 2006 Feb;72(2):193-5.
6
Histological transformation to signet-ring cell carcinoma in a patient with clinically aggressive poorly differentiated adenocarcinoma of the ascending colon after response to chemotherapy plus cetuximab: a case report.患者升结肠癌经化疗联合西妥昔单抗治疗后发生临床侵袭性低分化腺癌组织学转化为印戒细胞癌:病例报告。
World J Surg Oncol. 2023 Jun 7;21(1):172. doi: 10.1186/s12957-023-03053-2.
7
Primary signet ring cell carcinoma of the pancreas A case report about an extremely rare variant of pancreatic carcinoma.胰腺原发性印戒细胞癌 一种极其罕见的胰腺癌变异病例报告。
Ann Ital Chir. 2020 Dec 28;9:S2239253X2003443X.
8
Pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy.胰十二指肠切除术后残余胰腺的胰腺癌复发
JOP. 2006 Sep 10;7(5):473-7.
9
Signet-ring cell carcinoma of the ampulla of Vater.壶腹印戒细胞癌
J Formos Med Assoc. 2004 Oct;103(10):793-6.
10
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.整块切除静脉在治疗粘连于肠系膜上静脉-门静脉汇合处的胰腺腺癌中的理论依据。胰腺肿瘤研究小组。
Ann Surg. 1996 Feb;223(2):154-62. doi: 10.1097/00000658-199602000-00007.

引用本文的文献

1
Primary pancreatic signet ring cell carcinoma: a case series from China and literature review.原发性胰腺印戒细胞癌:来自中国的病例系列及文献综述
Discov Oncol. 2025 May 14;16(1):758. doi: 10.1007/s12672-025-02504-4.
2
A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?关于罕见类型胰腺癌的叙述性综述:它们应被视为胰腺导管腺癌进行治疗吗?
Ther Adv Med Oncol. 2024 Jul 26;16:17588359241265213. doi: 10.1177/17588359241265213. eCollection 2024.

本文引用的文献

1
Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study.胰腺印戒细胞癌患者的流行病学及预后分析:一项基于人群的研究。
BMC Gastroenterol. 2022 Nov 16;22(1):458. doi: 10.1186/s12876-022-02543-z.
2
Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature.原发性胰腺印戒细胞癌:一例报告并文献复习
J Pancreat Cancer. 2021 Jan 21;7(1):1-7. doi: 10.1089/pancan.2020.0013. eCollection 2021.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils.胰腺导管腺癌及其变异型:要点与陷阱。
Radiographics. 2020 Sep-Oct;40(5):1219-1239. doi: 10.1148/rg.2020190184. Epub 2020 Jul 17.
5
Epidemiology of Signet Ring Cell Adenocarcinomas.印戒细胞腺癌的流行病学
Cancers (Basel). 2020 Jun 11;12(6):1544. doi: 10.3390/cancers12061544.
6
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.可切除及边界可切除胰腺癌患者的新辅助治疗
Front Oncol. 2020 Jan 31;10:41. doi: 10.3389/fonc.2020.00041. eCollection 2020.
7
Primary signet ring cell carcinoma of the pancreatic head: A case report.胰腺头部原发性印戒细胞癌:一例报告。
Clin Case Rep. 2019 Oct 11;7(11):2235-2238. doi: 10.1002/ccr3.2475. eCollection 2019 Nov.
8
Primary signet ring cell carcinoma of the pancreas: Cytopathology review of a rare entity.胰腺原发性印戒细胞癌:一种罕见实体的细胞病理学回顾
Diagn Cytopathol. 2019 Dec;47(12):1314-1320. doi: 10.1002/dc.24324. Epub 2019 Oct 10.
9
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).吉西他滨与S-1新辅助化疗对比直接手术治疗可切除胰腺癌的随机II/III期试验(Prep-02/JSAP05)
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
10
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.